Related Experiment Video
Updated: Apr 30, 2026
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
[The course of coronary heart disease concurrent with peptic ulcer disease: clinical and pathogenetic aspects]
Insights
Eradication therapy significantly improved coronary heart disease (CHD) symptoms, reducing angina and nitroglycerin use. This therapy positively impacts CHD patients with concurrent peptic ulcer disease (PUD).
Area of Science:
- Cardiology
- Gastroenterology
Context:
- Coronary heart disease (CHD) and peptic ulcer disease (PUD) often coexist.
- Evaluating integrated treatment strategies is crucial for managing patients with multiple comorbidities.
Purpose:
- To assess the efficacy of eradication therapy in patients suffering from both CHD and PUD.
- To compare eradication therapy against antisecretory therapy and standard CHD treatment.
Summary:
- A study involving 112 patients with concurrent CHD and PUD randomized them into three groups: eradication therapy, antisecretory therapy, or CHD treatment alone.
- Eradication therapy led to a 62.6% reduction in angina attacks, a 70.4% decrease in nitroglycerin use, and a 45.3% increase in exercise tolerance.
- Antisecretory therapy showed moderate improvements, while the control group had no significant changes.
Impact:
- Eradication therapy demonstrates a significant antianginal effect, improving the clinical course of CHD in patients with PUD.
- This suggests a link between H. pylori eradication and cardiovascular health improvements.
- Findings support incorporating eradication therapy into the management of patients with comorbid CHD and PUD.
Aim:
To make a comprehensive evaluation of the efficiency of eradication therapy in patients with coronary heart disease (CHD) concurrent with peptic ulcer disease (PUD).
Subjects And Methods:
The results of treatment were studied in 112 patients with CHD concurrent with PUD who were randomized into 3 groups: 1) adequate eradication therapy during treatment for CHD; 2) antisecretory therapy; 3) treatment for CHD only. The trend in the clinical symptoms of the diseases and the results of an exercise test were assessed.
Results:
After eradication therapy, Group 1 patients displayed a reduction in the frequency of angina attacks by 62.6% and weekly nitroglycerin needs by 70.4% and an increase in exercise tolerance by 45.3%. In Group 2 patients on antisecretory therapy, the similar indicators changed by 30.7, 21.2, and 26.5%, respectively. Group 3 patients showed no significant change in the study indicators.
Conclusion:
The findings suggest that eradication therapy has a positive impact on the course of CHD, which manifests itself as an antianginal effect and hence a change in the clinical picture.
Related Concept Videos
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:24Peptic Ulcer Disease II: Pathophysiology
01:25Peptic Ulcer Disease III: Clinical Manifestations and Complications
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:25Peptic Ulcer Disease I: Introduction
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...